• Explore /
  • Poster
  • / Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design.

Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design.

Abstract Poster

Authors

null

Arun Azad

Peter MacCallum Cancer Centre, Melbourne, Australia

Arun Azad , Marco Antonio Badillo , Qiang Dong , Alicia K. Morgans , Dana E. Rathkopf , Karie Runcie , Tian Zhang , Raj Pruthi , Amitabha Bhaumik , Suneel Mundle , Sharon McCarthy , Angela Mennicke Lopez- Gitlitz , Jennifer Whalen , Ashita S. Batavia , Clark Musto , Shir Netanel , Daniel P. Sanchez , Neeraj Agarwal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05884398

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS236)

DOI

10.1200/JCO.2024.42.4_suppl.TPS236

Abstract #

TPS236

Poster Bd #

P19

Abstract Disclosures

Similar Posters

First Author: Rahul Raj Aggarwal

First Author: Kim N. Chi

First Author: Nabiel Ali Mir

Poster

2024 ASCO Genitourinary Cancers Symposium

Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS)

Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS)

First Author: Benjamin L. Maughan